10x Genomics TXG
85.71
1.60
1.90%
as of 25 Sep
- Market cap
- $11.1B
- P/E
- 0.0×
Follow TXG
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
8.08 | 4.26 | 3.17 | 2.29 | |
P/FCF ratio |
41.38 | 22.48 | 15.76 | 18.19 | |
P/Operating CF |
293.60 | 104.27 | 49.90 | 33.95 | |
P/B ratio |
6.04 | 3.34 | 2.56 | 1.87 | |
Price to Tangible BV |
6.58 | 3.63 | 2.79 | 2.05 | |
EV/Sales |
7.34 | 3.57 | 2.50 | 1.69 | |
EV/EBITDA |
0.00 | 323.75 | 0.00 | 0.00 | |
EV/Operating CF |
35.64 | 17.85 | 11.83 | 12.23 | |
EV/FCF |
37.61 | 18.83 | 12.46 | 13.43 | |
Quick Ratio |
5.09 | 5.25 | 3.95 | 3.93 | |
Current Ratio |
5.69 | 5.90 | 4.46 | 4.48 | |
Net Debt/EBITDA |
93.22 | 76.15 | 63.41 | 25.14 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.61 | 0.67 | 0.66 | 0.65 | |
Operating CF/Net income |
(0.95) | (1.94) | (2.51) | (1.57) | |
Capex/Depreciation |
(0.12) | (0.16) | (0.16) | (0.05) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
37.60% | 37.69% | 33.71% | 38.38% | |
Selling, General and Administrative Expense of Revenue |
52.08% | 44.00% | 46.15% | 50.57% | |
Intangible Assets out of Total Assets |
0.07 | 0.06 | 0.06 | 0.07 | |
Share Based Compensation of Revenue |
16.96% | 15.01% | 15.19% | 16.96% | |
Graham Net Nets |
0.09 | 0.17 | 0.22 | 0.28 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.54%) | (0.80%) | (2.15%) | (5.30%) | |
Free Cash Flow Yield |
2.42% | 4.45% | 6.35% | 5.50% | |
Revenue per Share |
1.16 | 1.18 | 1.33 | 1.19 | |
Operating CF per Share |
0.13 | 0.20 | 0.33 | 0.34 | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
0.12 | 0.19 | 0.31 | 0.34 | |
Cash per Share |
4.25 | 4.21 | 4.20 | 3.84 | |
Shareholders Equity per Share |
6.35 | 6.35 | 6.38 | 6.26 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.35 | 6.35 | 6.38 | 6.26 | |
Free Cash Flow |
15.39 | 24.52 | 39.00 | 42.53 | |
Working Capital |
556.16 | 556.14 | 531.00 | 512.50 | |
Capital Expenditures |
(1.59) | (1.60) | (1.78) | (0.69) | |
Net Current Asset Value |
470.15 | 468.30 | 439.41 | 417.59 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.00 | |
Net Profit Margin |
(11.87%) | (8.93%) | (9.79%) | (18.44%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
84.85 | 54.34 | 85.48 | 90.06 | |
Average Payables |
18.32 | 13.75 | 12.82 | 22.14 | |
Average Inventory |
60.79 | 64.10 | 69.72 | 78.00 | |
Average Assets |
1,005.02 | 959.58 | 980.00 | 982.58 | |
Average Common Equity |
799.41 | 760.61 | 753.23 | 753.96 |
Columns are period end dates